MedTrace Logo

506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)

NCT00684619 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-08-18

No results posted yet for this study

Summary

The purpose of this study is to determine whether Nelarabine is effective in the treatment of patients with T-ALL/NHL in order to achieve a complete remission followed by an early stem cell transplantation.

Conditions

  • T-ALL, T-NHL (Lymphoblastic)

Interventions

DRUG

Nelarabine

1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5

Sponsors & Collaborators

  • Goethe University

    lead OTHER

Principal Investigators

  • Dieter Hoelzer, MD, PhD · University Hospital of Frankfurt, Medical Dept. II

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00684619 on ClinicalTrials.gov